Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Acral Melanoma Clinical Trial

Official title:
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma: a Multicenter, Prospective, Randomized Controlled Trial

Status Recruiting

Clinical Trial Summary

It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05789043
Study type	Interventional
Source	Peking University Cancer Hospital & Institute
Contact	Jun Guo, Dr
Phone	010-88121122
Email	guoj307@126.com
Status	Recruiting
Phase	Phase 3
Start date	March 21, 2023
Completion date	February 15, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05512481` - Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma	Phase 2
Recruiting	`NCT04119024` - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05628883` - Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma	Phase 1
Recruiting	`NCT04331093` - Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma	Phase 2
Not yet recruiting	`NCT05436990` - Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor	Phase 2
Completed	`NCT00788775` - Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma	Phase 2
Recruiting	`NCT05086692` - A Beta-only IL-2 ImmunoTherapY Study	Phase 1/Phase 2